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EMCDDA–Europol Joint Report on a new psychoactive 
substance: 1-(4-cyanobutyl)-N-(2-phenylpropan-2-yl)
indazole-3-carboxamide (CUMYL-4CN-BINACA)
In accordance with Article 5 of Council Decision 2005/387/JHA on 
the information exchange, risk assessment and control of new 
psychoactive substances
About this series
EMCDDA–Europol Joint Report publications examine the detailed information 
provided by the EU Member States on individual new psychoactive substances. 
Information is collected from the Reitox network, the Europol National Units and the 
national competent authorities of the European Medicines Agency.
Each Joint Report serves as the basis upon which the decision to conduct a risk 
assessment of the new psychoactive substance is taken. It is part of the three-step 
procedure involving information exchange, risk assessment and decision-making in the 
framework of Council Decision 2005/387/JHA.
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I 1. Introduction
Article 5.1 of Council Decision 2005/387/JHA (1) (hereinafter 
the ‘Council Decision’) stipulates that ‘Where Europol and the 
EMCDDA, or the Council, acting by a majority of its members, 
consider that the information provided by the Member State 
on a new psychoactive substance merits the collection of 
further information, this information shall be collated and 
presented by Europol and the EMCDDA in the form of a Joint 
Report.’ The Joint Report shall be submitted to the Council of 
the European Union, the European Medicines Agency (EMA), 
and the European Commission.
In March 2017, the EMCDDA and Europol examined the 
available information on the new psychoactive substance 
1-(4-cyanobutyl)-N-(2-phenylpropan-2-yl)indazole-3-
carboxamide, commonly known as CUMYL-4CN-BINACA, 
through a joint assessment based upon the following criteria:
1. the amount of the material seized;
2. evidence of organised crime involvement;
3. evidence of international trafficking;
4. analogy with better-studied compounds;
5. evidence of the potential for further (rapid) spread; and,
6. evidence of cases of serious intoxication or fatalities.
The EMCDDA and Europol agreed that the information 
collected on CUMYL-4CN-BINACA satisfied criteria 1, 4, 5 and 
6. The two agencies therefore concluded that sufficient 
information had been accumulated to merit the production of 
a Joint Report on CUMYL-4CN-BINACA as stipulated by 
Article 5.1 of the Council Decision.
I 2. Information collection process
In compliance with the provisions of the Council Decision, on 
25 April 2017 the EMCDDA and Europol launched a procedure 
for the collection of information on CUMYL-4CN-BINACA, in 
order to prepare the Joint Report. The information was 
collected mainly through the Reitox national focal points in the 
Member States, Turkey and Norway as well as the Europol 
National Units. In addition, the EMA collected information 
through the national competent authorities responsible for 
human and veterinary medicinal products in the Member 
States as well as in Norway, Iceland and Liechtenstein. The 
EMA also provided information as relevant to the centralised 
procedure for authorising medicinal products. The information 
collection process was largely concluded by 6 June 2017.
(1) OJ L 127, 20.5.2005, p. 32.
Information collected by Europol
Europol asked the Europol National Units to provide 
information on:
 ¡ the level of production of CUMYL-4CN-BINACA in their 
country;
 ¡ the level of distribution of CUMYL-4CN-BINACA in their 
country;
 ¡ the level of trafficking of CUMYL-4CN-BINACA in their 
country, both for internal, transit or export purposes;
 ¡ the number of seizures of CUMYL-4CN-BINACA in their 
country, the total amount of the seizures, country of origin, 
details on the physical forms (including photos);
 ¡ the role of organised crime, or criminal groups, in the 
production, distribution and trafficking of CUMYL-4CN-
BINACA in their country;
 ¡ any known aspect of violence and/or money laundering 
relating to the production and trafficking of CUMYL-4CN-
BINACA.
Europol received responses from 16 Member States (2).
Information collected by the EMA
According to Article 5.3 of the Council Decision, the EMA 
requested that the national competent authorities responsible 
for human and veterinary medicinal products in the Member 
States, Norway, Iceland and Liechtenstein, provide information 
on whether:
 ¡ the new psychoactive substance CUMYL-4CN-BINACA has 
obtained a marketing authorisation;
 ¡ the new psychoactive substance CUMYL-4CN-BINACA is 
the subject of an application for a marketing authorisation;
 ¡ a marketing authorisation that had been granted in respect 
of the new psychoactive substance CUMYL-4CN-BINACA 
has been suspended.
Twenty-three countries provided a response to the EMA’s 
request regarding human and/or veterinary medicinal 
products (3). The EMA also provided information as relevant to 
the centralised procedure for authorising human and 
veterinary medicinal products.
(2) In alphabetical order: Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech 
Republic, Finland, Germany, Greece, Latvia, Lithuania, Luxembourg, Romania, 
Slovakia, Slovenia and Spain.
(3) Austria, Belgium, Denmark, Estonia, Finland, Germany, Greece, Ireland, Latvia, 
Norway, Poland, Spain, Sweden and the United Kingdom provided a response in 
relation to human and veterinary medicinal products. Croatia, Czech Republic, 
Hungary, Italy and the Netherlands provided a response in relation to human 
medicinal products. France, Portugal, Slovakia and Slovenia provided a response 
in relation to veterinary medicinal products.
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Furthermore, in anticipation of Article 7.3 of the Council 
Decision in relation to the manufacturing of medicinal 
products in the European Union, the EMA also requested 
information on whether the new psychoactive substance 
CUMYL-4CN-BINACA is used to manufacture a medicinal 
product:
 ¡ which has been granted a marketing authorisation;
 ¡ for which an application has been made for a marketing 
authorisation;
 ¡ for which a marketing authorisation has been suspended 
by a competent authority.
Twenty-three countries (4) provided a response to the EMA’s 
request in this regard. The EMA also provided information as 
relevant to the centralised procedure for authorising human 
and veterinary medicinal products.
Information collected by the EMCDDA
The EMCDDA collected information through:
 ¡ a structured questionnaire to the Reitox national focal 
points. The EMCDDA received replies from 27 Member 
States (5), as well as Turkey and Norway;
 ¡ reports previously provided to the European Union Early 
Warning System, including EMCDDA–Europol Reporting 
Forms and Progress Reports and Final Reports;
 ¡ routine monitoring of open source information;
 ¡ a specific information request to the World Health 
Organization on whether or not CUMYL-4CN-BINACA is 
under assessment by the United Nations system;
 ¡ a search of open source information conducted specifically 
for the production of the Joint Report which included: 
scientific and medical literature, official reports, grey 
literature, internet drug discussion forums and related 
websites (hereafter, ‘user websites’) and online vendors 
selling CUMYL-4CN-BINACA.
The EMCDDA would like to thank the United States Drug 
Enforcement Administration for kindly providing unpublished 
in vitro data on the pharmacology of CUMYL-4CN-BINACA (US 
DEA, 2017).
Thus, the information included in sections 3.2.1 and 3.3 of the 
Joint Report was provided by Europol, while the EMCDDA 
provided information included in sections 3.1, 3.2.2, 3.4, 3.5, 
3.6, 3.7, 3.8.1, 3.8.2 and 3.8.3 (in part). The information 
(4) Austria, Belgium, Denmark, Estonia, Finland, Germany, Greece, Ireland, Latvia, 
Norway, Poland, Spain, Sweden and the United Kingdom provided a response in 
relation to human and veterinary medicinal products. Croatia, Czech Republic, 
Hungary, Italy and the Netherlands provided a response in relation to human 
medicinal products. France, Portugal, Slovakia and Slovenia provided a response 
in relation to veterinary medicinal products.
(5) A reply was not received from Slovakia. 
included in sections 3.8.3 (in part), and 4 was provided by the 
EMA. Images of the seizures and collected samples reported 
to the EMCDDA are provided in Annex 1.
 3.  Information required by Article 5.2 of 
the Council Decision
The order and titles of subsections 3.1 to 3.8 and section 4, 
below, are as they appear in Article 5.2(a) to (h) and Article 
5.3(a) to (c) of the Council Decision; sections are cross-
referenced with those set down in the Council Decision.
 3.1  Chemical and physical description, including the 
names under which the new psychoactive 
substance is known (Article 5.2(a) of the Council 
Decision)
Chemical description and names
1-(4-cyanobutyl)-N-(2-phenylpropan-2-yl)indazole-3-
carboxamide is commonly referred to as CUMYL-4CN-
BINACA.
CUMYL-4CN-BINACA is a synthetic cannabinoid receptor 
agonist.
CUMYL-4CN-BINACA has an indazole core, which is 
a common structural feature in many of the synthetic 
cannabinoids monitored by the EMCDDA. The common name 
for the substance is derived after its structural features (6): 
a cumyl group (CUMYL), a cyano group linked to the 4-position 
(4-CN) of a butyl tail (B), an indazole core (INA), and 
a carboxamide linker (CA).
Two synthetic cannabinoid receptor agonists have been 
recently controlled under Schedule II of the United Nations 
Convention on Psychotropic Substances of 1971: JWH-018 (7) 
and AM-2201 (8). In addition, MDMB-CHMICA, 5F-APINACA 
(5F-AKB48) and XLR-11 will be included in the same schedule.
The molecular structure, molecular formula, and molecular 
mass of CUMYL-4CN-BINACA are provided in in Figure 1.
(6) Different naming systems exist and are utilized for applying short/code 
names to synthetic cannabinoids.
(7) Naphthalen-1-yl(1-pentyl-1H-indol-3-yl)methanone
(8) 1-(5-Fluoropentyl)-1H-indol-3-yl]-(naphthalen-1-yl)methanone
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CUMYL-4CN-BINACA has a positional isomer, where the 
cyanobutyl tail is attached to the nitrogen at position 2 of the 
indazole (9). Both isomers have the same molecular formula 
and molecular weight which result in very similar mass 
spectra. However, they can be differentiated based on their 
retention time and it would be expected that the infrared (IR) 
and nuclear magnetic resonance spectra (NMR) would be 
different.
Commonly used names: 
CUMYL-4CN-BINACA
Systematic (IUPAC) name: 
1-(4-cyanobutyl)-N-(2-phenylpropan-2-yl)indazole-3-
carboxamide
Other chemical names: 
1-(4-cyanobutyl)-N-(1-methyl-1-phenyl-ethyl)indazole-3-
carboxamide;  
1-(4-cyanobutyl)-N-(1-methyl-1-phenylethyl)-1H-indazole-3-
carboxamide;  
1-(4-cyanobutyl)-N-(2-fenylpropan-2-yl)-1H-indazol-3-
karboxamid (Swedish)
Other names and code names: 
SGT-78; 4-CN-CUMYL-BINACA; CUMYL-CB-PINACA; CUMYL-
CYBINACA; 4-cyano CUMYL-BUTINACA
(9) The positional isomer of CUMYL-4CN-BINACA is referred to as ‘4-cyano 
CUMYL-BUTINACA isomer 2’ by Cayman Chemical (https://www.caymanchem.
com/product/20748). 
FIGURE 1 
Molecular structure, molecular formula, and molecular mass 
of CUMYL-4CN-BINACA
N
N
O
HN
N
CUMYL-4CN-BINACA
Molecular formula C22H24N4O
Molecular mass 360.46
Chemical Abstracts Service (CAS) registry numbers (10): 
1631074-54-8
IUPAC International Chemical Identifier Key (InCHI Key) (11): 
JGTSOWOPISVAHG-UHFFFAOYSA-N
The REACH registered substances database hosted by the 
European Chemicals Agency (ECHA) was searched using the CAS 
registry numbers listed above. The searches returned no hits.
Physical description
In its pure form CUMYL-4CN-BINACA is a crystalline solid.
CUMYL-4CN-BINACA has been seized as a powder and in herbal 
material. A more detailed description of seizures and collected 
samples can be found in section 3.2.1 and section 3.2.2.
Chemical stability and typical reactions
CUMYL-4CN-BINACA is reported to be stable if stored in 
accordance with information listed in the safety data sheet (12).
Detection and analysis
Reference materials are available for CUMYL-4CN-BINACA (13) 
and CUMYL-4CN-BINACA 2-isomer (14).
Methods documented in the literature for the detection of 
CUMYL-4CN-BINACA include: gas chromatography–mass 
spectrometry (GC-MS), high performance liquid 
chromatography time-of-flight (HPLC-TOF), Fourier transform 
infrared spectroscopy attenuated total reflectance (FTIR-
ATR), gas chromatography–mass spectrometry– infrared 
(GC-MS-IR) condensed phase, ion chromatography (IC), 
1H-NMR and 13C-NMR (Slovenian National Forensic 
Laboratory, 2016a and 2016b; Bowden and Williamson, 2014).
Quantification of CUMYL-4CN-BINACA in products can be 
carried out according to the general procedure described by 
the UNODC (UNODC, 2013).
(10) The Chemical Abstract Service Registry Number (CAS RN) is a unique 
numeric identifier assigned by the Chemical Abstract Service Division of the 
American Chemical Society to a specific, single chemical substance.
(11) InChI Key is a unique, non-proprietary stuctural identifier of chemical 
substances useful in electronic sources.
(12) Cayman Chemical, 2016. Safety data sheet of 4-cyano CUMYL-BUTINACA. 
Available at: https://www.caymanchem.com/msdss/20194m.pdf
(13) Cayman Chemical Company. ‘4-cyano CUMYL-BUTINACA’,  
https://www.caymanchem.com/product/20194
(14) Cayman Chemical Company. ‘4-cyano CUMYL-BUTINACA isomer 2’,  
https://www.caymanchem.com/product/20748
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 3.2  Information on the frequency, circumstances 
and/or quantities in which a new psychoactive 
substance is encountered, and information on the 
means and methods of manufacture of the new 
psychoactive substance (Article 5.2(b) of the 
Council Decision)
The data reported to Europol discussed in section 3.2.1 may 
overlap with the data reported to the EMCDDA discussed in 
section 3.2.2.
3.2.1 Information provided to Europol
Europol received replies from 16 Member States (Austria, 
Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Finland, 
Germany, Greece, Latvia, Lithuania, Luxembourg, Romania, 
Slovakia, Slovenia and Spain).
Thirteen countries reported that they have no available 
information on CUMYL-4CN-BINACA (Austria, Belgium, 
Bulgaria, Croatia, Cyprus, Czech Republic, Finland, Greece, 
Latvia, Lithuania, Luxembourg, Slovakia and Spain).
Three countries provided information on CUMYL-4CN-BINACA 
(Germany, Romania and Slovenia).
The level of production
No information was received in relation to the production of 
CUMYL-4CN-BINACA.
The level of distribution
A total of 20 seizures were reported by two Member States: 
Germany (19) and Romania (1). Slovenia reported a collected 
sample (section 3.2.2).
 ¡ Germany reported 7 seizures in 2016 (6 small seizures of 
herbal material and 10 ml of liquid), and 12 seizures in 2017 
(10 small seizures of herbal material, and two seizures of 
500 and 193 g of powder).
 ¡ Romania reported 1 seizure of 0.6 g.
The level of trafficking
Information related to trafficking routes is limited to the 
seizures reported above.
3.2.2 Information provided to the EMCDDA
The EMCDDA received responses from 27 Member States (5), 
as well as from Turkey and Norway. Of these, 10 Member 
States (Estonia, France, Germany, Hungary, Lithuania, 
Romania, Slovenia, Spain, Sweden and the United Kingdom) 
and Turkey reported detections of CUMYl-4CN-BINACA (15).
It is important to note that detections of CUMYl-4CN-BINACA 
may be under-reported since the substance is not routinely 
screened for. Three Member States (Austria, Slovenia and 
Sweden) reported that CUMYl-4CN-BINACA is part of routine 
screening in some (but not all) of their laboratories.
Seizures
In total, 2 460 seizures of CUMYl-4CN-BINACA were reported 
to the EMCDDA by nine Member States and Turkey: Estonia (1 
seizure), France (1), Germany (4), Hungary (197), Lithuania (1), 
Romania (1), Spain (1), Sweden (66), the United Kingdom (2) 
and Turkey (2 186). The majority of the seizures comprise 
police and customs cases, with additional seizures taking 
place in custodial settings.
These seizures included:
 ¡ 233 seizures of herbal material, reported by five Member 
States (Germany, Hungary, Romania, Sweden, the United 
Kingdom), amounting to a total of 3.6 kg. In addition, Turkey 
reported 2 186 seizures of herbal material amounting to 
over 257 kg (16). In the herbal materials seized, CUMYL-
4CN-BINACA was commonly found mixed with other 
synthetic cannabinoids. Seizures included herbal materials, 
powders, liquids, blotters and unspecified physical forms. 
A summary is provided below.
 ¡ 40 seizures of powder, reported by five Member States 
(France, Germany, Lithuania, Spain and Sweden), 
amounting to a total of just under 52 kg. The largest single 
seizure of powder was reported by Spanish customs, and 
amounted to 50 kg, which originated in China. In a seizure 
that took place in January 2017 at Rossy Airport in France, 
customs intercepted over 1.5 kilograms of powder which 
also contained the synthetic cathinone 4-CEC 
(4-chloroethcathinone), on its way from China to the 
Netherlands.
No quantitative information on purity was provided to the 
EMCDDA.
Collected samples
One collected sample was reported by Slovenia, which 
consisted of 5 g of off-white powder purchased online from 
China.
(15) ‘Detections’ is an all-encompassing term and may include seizures and/or 
collected and/or biological samples that are analytically confirmed. Seizure 
means a substance available (seized) through law enforcement activities (police, 
customs, border guards, etc.). Collected samples are those that are actively 
collected by drug monitoring systems (such as test purchases) for monitoring 
and research purposes. Biological samples are those from human body fluids 
(urine, blood, etc.) and/or specimens (tissues, hair, etc.). 
(16) This is a minimum estimate provided by the Turkish national focal point.
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Biological samples
Serious adverse events with confirmed exposure to CUMYL-
4CN-BINACA from biological samples are discussed in 
section 3.4.2.
In addition to these, 135 detections where CUMYL-4CN-
BINACA was analytically confirmed in biological samples were 
reported by two Member States: Hungary (133) and Sweden 
(2) (17). Detections include:
 ¡ 16 cases of persons suspected of driving under the 
influence of drugs (including five traffic accidents), all 
reported by Hungary;
 ¡ 119 cases reported as aggregated data associated with 
forensic case work (details not specified).
 3.3  Information on the involvement of organised 
crime in the manufacture or trafficking of the new 
psychoactive substance (Article 5.2(c) of the 
Council Decision)
No information concerning the involvement of organised crime 
in the manufacture and/or trafficking of the CUMYL-4CN-
BINACA was provided.
Money laundering aspects
No information was received on money laundering in 
connection with the production and/or trafficking of CUMYL-
4CN-BINACA.
Violence in connection with production, wholesale and 
distribution
No information was received on incidents of violence in 
connection with the production, wholesale and/or trafficking 
of CUMYL-4CN-BINACA.
 3.4  A first indication of the risks associated with the 
new psychoactive substance, including the health 
and social risks, and of the characteristics of 
users — Article 5.2(d) of the Council Decision
3.4.1 Health risks
Pharmacology and toxicology
Limited data suggests that CUMYL-4CN-BINACA is a CB
1
 
receptor agonist (US DEA, 2017) that shares some similarities 
(17) In addition, Turkey reported 694 samples (blood, hair and urine) which may 
contain duplicates and therefore have not been included in the total count. 
with the major psychoactive constituent of cannabis (–)-trans-
Δ9-tetrahydrocannabinol (THC) and synthetic cannabinoids 
such as JWH-018 and MDMB-CHMICA (EMCDDA, 2017; 
Järbe and Raghav, 2017; Pertwee, 2014; Reggio, 2009).
The acute effects of THC (and consequently cannabis) include: 
relaxation, euphoria, lethargy, depersonalisation, distorted 
perception of time, impaired motor performance, 
hallucinations, paranoia, confusion, fear, anxiety, dry mouth, 
reddening of the conjunctivae of the eyes, tachycardia, and, 
nausea and vomiting. THC also has an abuse liability and 
dependence potential (Pertwee, 2014; Wiley et al., 2016). 
Similar effects to THC/cannabis have been reported for 
synthetic cannabinoids such as CUMYL-4CN-BINACA. In 
some cases, the effects are reported to be more pronounced/
severe (EMCDDA, 2017).
Compared to cannabis, severe and fatal poisoning appears to 
be more common with synthetic cannabinoids (EMCDDA, 
2017; Tait et al., 2016). Poisoning may include rapid loss of 
consciousness/coma, cardiovascular effects (such as 
hypertension, tachycardia, bradycardia, chest pain, myocardial 
infarction, and stroke), seizures and convulsions, vomiting/
hyperemesis, delirium, agitation, psychosis, and, aggressive 
and violent behaviour. Sudden death has also been reported. 
The mechanisms of this toxicity are poorly understood (Tai 
and Fantegrossi, 2016), but factors that are likely to play an 
important role are the potency of the substances and the 
doses that users are exposed to. In addition, some of the 
effects of poisoning — such as loss of consciousness or 
behavioural effects — may place users at additional risks such 
as choking on vomitus, drowning, or self-harm.
There is no antidote to poisoning caused by synthetic 
cannabinoids.
In general, the use of herbal smoking mixtures containing 
synthetic cannabinoids appears to pose a high risk of 
poisoning. This is because manufacturers guess the amount 
of cannabinoid(s) to add to the herbal material, and the 
manufacturing process makes it difficult to dilute them 
sufficiently and distribute them consistently throughout the 
material. This can result in mixtures that contain a large 
amount of highly potent cannabinoid, as well as ‘hot pockets’ 
where the cannabinoid is highly concentrated within parts of 
the herbal material (e.g. Schäper et al., 2016). Together, this 
makes it difficult for users to control the dose that they are 
exposed to. As these mixtures are typically smoked as 
cigarettes (‘joints’), users can inadvertently administer a toxic 
dose; in some cases, a small number of puffs from a cigarette 
have been sufficient to cause severe poisoning. Reflecting 
these risks, smoking mixtures have caused a large number of 
outbreaks of mass poisonings in recent years (Adams et al., 
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2017; Kasper et al., 2015; Schwartz et al., 2015; Shevyrin et al., 
2015; Trecki et al., 2015; Tyndall et al., 2015).
While there is limited data for CUMYL-4CN-BINACA, the 
chronic health risks might share similarities to cannabis and 
other synthetic cannabinoids. This may include dependence.
3.4.2 Serious adverse events
Acute intoxications reported to the EMCDDA
A total of five acute intoxications with confirmed exposure to 
CUMYL-4CN-BINACA were reported by Hungary (4 cases) and 
Sweden (1). The cases occurred during 2016. No further 
details are available on the cases from Hungary.
In the case from Sweden, it was reported that the individual 
was found outside and lost consciousness. The patient was 
treated in intensive care. The only other substances detected 
were amlodipine and naproxen. No further details are 
available.
Deaths reported to the EMCDDA
A total of 11 deaths with confirmed exposure to CUMYL-4CN-
BINACA were reported by Hungary (3 cases) and Sweden (8). 
The cases in Hungary occurred in 2016. No further details are 
available on these cases. The cases in Sweden occurred 
between September 2016 and November 2016.
Of the eight deaths reported by Sweden, seven were male 
(88 %) and one was female (12 %). The males were aged 
between 29 and 61 years (mean 43.3, median 40); the female 
was aged 29. In two cases, no other substances were 
detected. In the remaining six cases, other substances were 
detected including central nervous system depressants (such 
as benzodiazepines, gabapentinoids, and opioids). Where 
known, most of the individuals were found dead; in at least 
some cases this was in a home environment. In at least five 
cases, CUMYL-4CN-BINACA was the cause of death or 
contributed to the death.
3.4.3 Characteristics of users
Similar to other synthetic cannabinoids, CUMYL-4CN-BINACA 
is sold and used as a ‘legal’ substitute for cannabis (EMCDDA, 
2009; EMCDDA, 2017). It is commonly administered by 
smoking a cigarette of herbal mixture that has been laced with 
the substance. Because these products rarely state the 
ingredients, most users will be unaware that they are using 
CUMYL-4CN-BINACA.
People who use CUMYL-4CN-BINACA may include 
recreational users, high-risk drug users, and groups who 
experiment with the substance (such as psychonauts). This 
may also include individuals who are subject to drug testing 
(such as people in drug treatment, prisoners, and drivers) 
because some drug tests/screens will be unable to detect 
CUMYL-4CN-BINACA. In the past few years, synthetic 
cannabinoids have become increasingly used by vulnerable 
groups (such as the homeless and prisoners).
3.4.4 Social risks
While there is limited data for CUMYL-4CN-BINACA, the social 
risks might share some similarities with cannabis and other 
synthetic cannabinoids.
Of particular note is that synthetic cannabinoids are 
increasingly used by vulnerable groups, such as the homeless 
and prisoners. Reports suggest that this has caused new 
health and social problems as well as exacerbated existing 
ones for these groups. For example, in prisons, alongside the 
adverse health effects, the market in synthetic cannabinoids 
has been linked to an increase in aggression, violence, 
bullying, and debt. In some cases this has caused a serious 
threat to the overall safety and security of the prison 
environment (Blackman et al., 2017; HMIP, 2015; Ralphs et al., 
2017; User Voice, 2016).
 3.5  Information on whether or not the new substance 
is currently under assessment, or has been under 
assessment, by the UN system (Article 5.2(e) of 
the Council Decision)
The World Health Organization is the specialised United 
Nations agency designated for the evaluation of the medical, 
scientific and public health aspects of psychoactive 
substances under the Single Convention on Narcotic Drugs, 
1961 and the Convention on Psychotropic Substances, 1971.
On 1 May 2017, the World Health Organization informed the 
EMCDDA that CUMYL-4CN-BINACA is currently not under 
assessment and has not been under assessment by the UN 
system.
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 3.6  The date of notification on the Reporting Form of 
the new psychoactive substance to the EMCDDA 
or to Europol (Article 5.2(f) of the Council 
Decision)
The first official EMCDDA–Europol notification of CUMYL-
4CN-BINACA dates from 4 March 2016 from the Hungarian 
national focal point. The Reporting Form details the 
identification of CUMYL-4CN-BINACA in a seizure of 1 g of 
green herbal material seized by the Hungarian Police in 
Orosháza, in January 2016. The substance was analytically 
confirmed by ATR-FT-IR, GC-MS, 1H-NMR and 13C-NMR by the 
Hungarian Institute for Forensic Science.
CUMYL-4CN-BINACA was added to the list of new 
psychoactive substances monitored by the EMCDDA and 
Europol through the European Union Early Warning System. 
A profile of the substance was created on the European 
Database on New Drugs (EDND). Since then, analytical details 
and other information, including a public health alert, have 
been exchanged between the EMCDDA, Europol, and the 
Member States, Turkey, and Norway, on an ad hoc basis; the 
European Commission and the EMA have been kept duly 
informed.
It is important to note that CUMYL-4CN-BINACA was first 
identified in a seizure in Estonia in October 2015. CUMYL-
4CN-BINACA was identified in 7.65 g of powder by Customs in 
Tallinn. The origin of the seizure was the Czech Republic.
 3.7  Information on whether or not the new 
psychoactive substance is already subject to 
control measures at national level in a Member 
State (Article 5.2(g) of the Council Decision)
Seven Member States (Croatia, Cyprus, Finland, Latvia, 
Lithuania, Luxembourg and Sweden) reported that CUMYL-
4CN-BINACA is controlled under drug control legislation.
Four Member States (Austria, Germany, Hungary and Poland) 
and Turkey reported that CUMYL-4CN-BINACA is controlled 
under specific new psychoactive substances control 
legislation.
Sixteen Member States (Belgium, Bulgaria, Czech Republic, 
Denmark, Estonia, France, Greece, Ireland, Italy, Malta, the 
Netherlands, Portugal, Romania, Slovenia, Spain and the 
United Kingdom) reported that CUMYL-4CN-BINACA is not 
subject to control measures at the national level.
Norway reported that it is not known whether CUMYL-4CN-
BINACA is controlled, as the substance is not covered by any 
of the generic groups defined in the drug control legislation. It 
may be covered by the medicinal products legislation if its 
effects are proved by scientific evidence.
Slovakia did not provide information on the control status of 
CUMYL-4CN-BINACA.
 3.8  Further information (Article 5.2(h) of the Council 
Decision)
3.8.1  The chemical precursors that are known to have 
been used for the manufacture of the substance
No information was reported by the Member States, Turkey or 
Norway, about the chemical precursors or manufacturing 
methods used to make the CUMYL-4CN-BINACA which has 
been detected within Europe.
The synthesis of CUMYL-4CN-BINACA was first described in 
a 2014 patent (Bowden and Williamson, 2014). The patent 
investigated new indole and indazole cannabinoids and the 
applications of these compounds.
The published synthetic method for CUMYL-4CN-BINACA 
(compound ‘SGT-78’ in the patent) describes the reaction of 
1H- Indazole- 3- carboxylic acid (18) with 5-bromo-pentanetrilie 
(19) to yield 1- (4- cyanobutyl) -1H-indazole- 3- carboxylic acid 
(20). This substance is then reacted with α, α- dimethyl- 
benzenemethanamine (21) to give the final product.
3.8.2  The mode and scope of the established or 
expected use of the new substance
No studies were identified that have examined the mode and 
scope of established or expected use of CUMYL-4CN-BINACA. 
Given the limited information currently available, the relevant 
information has been included in the previous sections.
3.8.3  Other use of the new psychoactive substance 
and the extent of such use, the risks associated 
with this use of the new psychoactive 
substance, including the health and social risks
No information was provided by the Member States, Turkey or 
Norway that indicated that CUMYL-4CN-BINACA had any 
(18) CAS number: 4498-67-3
(19) aka bromo-4-cyanobutane/4-cyanobutyl-bromide; CAS number: 5414-21-1 
(20) CAS number: 1185897-54-4 
(21) Also called 2- phenyl- 2- propanamine/cumylamine.
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other use apart from in analytical reference materials and 
scientific research.
From the available information, it does not appear that 
CUMYL-4CN-BINACA is used in the manufacture of 
a medicinal product in the European Union. However, the data 
collection is incomplete and some countries indicated that 
this information is not known. It is understood that the 
collection of such information is a challenge in the absence of 
a database on the synthetic route of all medicinal products.
Eleven countries (Austria, Belgium, Croatia, Denmark, Finland, 
Greece, Italy, the Netherlands, Poland, Spain and the United 
Kingdom) reported that CUMYL-4CN-BINACA is not used to 
manufacture a medicinal product for human use. Eight 
countries (Czech Republic, Estonia, Germany, Hungary, 
Ireland, Latvia, Norway and Sweden) reported that it was 
unknown if CUMYL-4CN-BINACA is used to manufacture 
a medicinal product for human use.
In addition, the EMA reported that it is not known if CUMYL-
4CN-BINACA is used in the manufacture of medicinal 
products for human use and which are centrally authorised 
within the European Union.
Eleven countries (Austria, Belgium, Denmark, Finland, France, 
Greece, Latvia, Poland, Slovakia, Spain and the United 
Kingdom) provided information that CUMYL-4CN-BINACA is 
not used to manufacture a medicinal product for veterinary 
use. Seven countries (Estonia, Germany, Ireland, Norway, 
Portugal, Slovenia and Sweden) reported that it was unknown 
if CUMYL-4CN-BINACA is used to manufacture a medicinal 
product for veterinary use.
In addition, the EMA reported that it is not known if CUMYL-
4CN-BINACA is used in the manufacture of medicinal 
products for veterinary use and which are centrally authorised 
within the European Union.
 4.  Information from the EMA (Article 5.3 
of the Council Decision)
Nineteen countries (Austria, Belgium, Croatia, Czech Republic, 
Denmark, Estonia, Finland, Germany, Greece, Hungary, 
Ireland, Italy, Latvia, the Netherlands, Norway, Poland, Spain, 
Sweden and the United Kingdom) reported that:
 ¡ CUMYL-4CN-BINACA has not been granted a marketing 
authorisation as a medicinal product for human use;
 ¡ CUMYL-4CN-BINACA is not the subject of an application 
for a marketing authorisation as a medicinal product for 
human use;
 ¡ there had been no cases of suspended marketing 
authorisation in respect to CUMYL-4CN-BINACA as 
a human medicine.
Eighteen countries (Austria, Belgium, Denmark, Estonia, 
Finland, France, Germany, Greece, Ireland, Latvia, Norway, 
Poland, Portugal, Slovakia, Slovenia, Spain, Sweden and the 
United Kingdom) reported that:
 ¡ CUMYL-4CN-BINACA has not been granted a marketing 
authorisation as a medicinal product for veterinary use;
 ¡ CUMYL-4CN-BINACA is not the subject of an application 
for a marketing authorisation as a medicinal product for 
veterinary use;
 ¡ there had been no cases of suspended marketing 
authorisation in respect to CUMYL-4CN-BINACA as 
a veterinary medicine.
The EMA also reported that CUMYL-4CN-BINACA:
 ¡ has not been granted a marketing authorisation as 
a medicinal product for neither human nor veterinary use 
through the centralised procedure;
 ¡ is not the subject of an application for a marketing 
authorisation for neither human nor veterinary use through 
the centralised procedure;
 ¡ is not the subject of a suspended marketing authorisation 
for neither human nor veterinary use through the 
centralised procedure.
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I 5. Conclusion
CUMYL-4CN-BINACA is a synthetic cannabinoid and a CB
1
 
receptor agonist. It shares some pharmacological similarities 
with Δ9-tetrahydrocannabinol (THC), which is responsible for 
the major psychoactive effects of cannabis. In humans, 
CUMYL-4CN-BINACA appears to cause effects that resemble 
those of cannabis and other synthetic cannabinoids.
CUMYL-4CN-BINACA has been available in the European 
Union since at least October 2015 and has been detected in 
nine Member States and Turkey. More than 270 seizures have 
been made within the European Union, which includes more 
than 50 kg of powder and 3.6 kg of herbal material which has 
been laced with CUMYL-4CN-BINACA. This herbal material is 
typically sold as smoking mixtures; the products are marketed 
as ‘legal’ replacements to cannabis. Due to the way that these 
products are produced, it appears that users are at risk of 
serious poisoning. There are indications that the AB-
CHMINACA available on the market was synthesised by 
chemical companies based in China.
Eleven deaths with confirmed exposure to CUMYL-4CN-
BINACA have been reported by two Member States. In at least 
five of the deaths, CUMYL-4CN-BINACA was the cause of 
death or contributed to the death.
CUMYL-4CN-BINACA is currently not under assessment and 
has not been under assessment by the UN system. CUMYL-
4CN-BINACA is not subject to control measures in 16 Member 
States.
We conclude that the health and social risks caused by the 
manufacture, trafficking and use of CUMYL-4CN-BINACA, and 
the involvement of organised crime and possible 
consequences of control measures, could be thoroughly 
assessed through a risk assessment procedure in accordance 
with Article 6 of Council Decision 2005/387/JHA.
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